Click Here for 5% Off Your First Aladdin Purchase!

LY294002 - ≥98%, high purity , CAS No.154447-36-6

  • Moligand™
  • ≥98%
Item Number
L124970
Grouped product items
SKUSizeAvailabilityPrice Qty
L124970-10mg
10mg
In stock
$58.90
L124970-25mg
25mg
In stock
$71.90
L124970-50mg
50mg
In stock
$82.90
L124970-100mg
100mg
In stock
$105.90
L124970-250mg
250mg
In stock
$238.90
L124970-500mg
500mg
In stock
$337.90

PI3-kinase inhibitor

Basic Description

Synonyms154447-36-6|LY294002|LY 294002|2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one|LY-294002|2-morpholino-8-phenyl-4H-chromen-4-one|2-morpholin-4-yl-8-phenyl-4H-chromen-4-one|2-morpholin-4-yl-8-phenylchromen-4-one|2-(morpholin-4-yl)-8-phenyl-4H-chromen-4-one
Specifications & PurityMoligand™, ≥98%
Biochemical and Physiological MechanismsLY294002 is a potent inhibitor of PI 3-kinase, a protein in the phosphoinositide 3-kinase family of intercellular signal regulating enzymes. This compound is selective for PI 3-kinase p110 β (PI 3-Kβ) and PI 3-kinase p110 α (PI 3-Kα), although it will inh
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
NoteWherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Product Description

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation.
A potent blocker of PI 3-kinase/Akt signaling.

Associated Targets

CYP1A2 Tchem Cytochrome P450 1A2 2 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CDK1 Tchem Cyclin-dependent kinase 1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

DRD2 Tclin D(2) dopamine receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CYP3A4 Tclin Cytochrome P450 3A4 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ERBB2 Tclin Receptor tyrosine-protein kinase erbB-2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ELANE Tclin Neutrophil elastase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

EGFR Tclin Epidermal growth factor receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CDK2 Tchem Cyclin-dependent kinase 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

FLT4 Tclin Vascular endothelial growth factor receptor 3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

YES1 Tclin Tyrosine-protein kinase Yes 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HMGCR Tclin 3-hydroxy-3-methylglutaryl-coenzyme A reductase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HDAC6 Tclin Histone deacetylase 6 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

FLT3 Tclin Receptor-type tyrosine-protein kinase FLT3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

FGFR3 Tclin Fibroblast growth factor receptor 3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HRH1 Tclin Histamine H1 receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MET Tclin Hepatocyte growth factor receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SIGMAR1 Tclin Sigma non-opioid intracellular receptor 1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PLK4 Tchem Serine/threonine-protein kinase PLK4 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PIM1 Tchem Serine/threonine-protein kinase pim-1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PIK3CG Tclin Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PIM2 Tchem Serine/threonine-protein kinase pim-2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PIK3CB Tchem Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform 2 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PIM3 Tchem Serine/threonine-protein kinase pim-3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PTGS1 Tclin Prostaglandin G/H synthase 1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PRKCH Tchem Protein kinase C eta type 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PRKD1 Tchem Serine/threonine-protein kinase D1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CA2 Tclin Carbonic anhydrase 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

BTK Tclin Tyrosine-protein kinase BTK 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ATR Tchem Serine/threonine-protein kinase ATR 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AURKA Tchem Aurora kinase A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AURKB Tchem Aurora kinase B 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADRA2B Tclin Alpha-2B adrenergic receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADRA2C Tclin Alpha-2C adrenergic receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADORA2A Tclin Adenosine receptor A2a 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ACHE Tclin Acetylcholinesterase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ABL1 Tclin Tyrosine-protein kinase ABL1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AR Tclin Androgen receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AKT1 Tchem RAC-alpha serine/threonine-protein kinase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADORA1 Tclin Adenosine receptor A1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HTR2B Tclin 5-hydroxytryptamine receptor 2B 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CLK3 Tchem Dual specificity protein kinase CLK3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

EDNRA Tclin Endothelin-1 receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

GSK3B Tclin Glycogen synthase kinase-3 beta 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NOS2 Tchem Nitric oxide synthase, inducible 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NTRK1 Tclin High affinity nerve growth factor receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NOS1 Tchem Nitric oxide synthase, brain 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MTOR Tclin Serine/threonine-protein kinase mTOR 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

Pubchem Sid488179813
Pubchem Sid Urlhttps://pubchem.ncbi.nlm.nih.gov/substance/488179813
IUPAC Name 2-morpholin-4-yl-8-phenylchromen-4-one
INCHI InChI=1S/C19H17NO3/c21-17-13-18(20-9-11-22-12-10-20)23-19-15(7-4-8-16(17)19)14-5-2-1-3-6-14/h1-8,13H,9-12H2
InChi Key CZQHHVNHHHRRDU-UHFFFAOYSA-N
Canonical SMILES C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4
Isomeric SMILES C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4
PubChem CID 3973
Molecular Weight 307.35

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

38 results found

Lot NumberCertificate TypeDateItem
H2427172Certificate of AnalysisAug 14, 2024 L124970
H2427173Certificate of AnalysisAug 14, 2024 L124970
H2427175Certificate of AnalysisAug 14, 2024 L124970
I2224270Certificate of AnalysisJul 04, 2024 L124970
A2429198Certificate of AnalysisJan 12, 2024 L124970
A2429186Certificate of AnalysisJan 12, 2024 L124970
A2429199Certificate of AnalysisJan 12, 2024 L124970
A2429197Certificate of AnalysisJan 12, 2024 L124970
A2429196Certificate of AnalysisJan 12, 2024 L124970
A2429195Certificate of AnalysisJan 12, 2024 L124970
A2429194Certificate of AnalysisJan 12, 2024 L124970
A2429192Certificate of AnalysisJan 12, 2024 L124970
A2429191Certificate of AnalysisJan 12, 2024 L124970
A2429190Certificate of AnalysisJan 12, 2024 L124970
A2429189Certificate of AnalysisJan 12, 2024 L124970
A2429188Certificate of AnalysisJan 12, 2024 L124970
I2118363Certificate of AnalysisJan 02, 2024 L124970
K2309266Certificate of AnalysisOct 25, 2023 L124970
K2309265Certificate of AnalysisOct 25, 2023 L124970
K2309264Certificate of AnalysisOct 25, 2023 L124970
K2309263Certificate of AnalysisOct 25, 2023 L124970
I2118361Certificate of AnalysisJul 07, 2023 L124970
E2322308Certificate of AnalysisApr 27, 2023 L124970
E2322341Certificate of AnalysisApr 27, 2023 L124970
E2322305Certificate of AnalysisApr 27, 2023 L124970
E2322301Certificate of AnalysisApr 27, 2023 L124970
E2322297Certificate of AnalysisApr 27, 2023 L124970
E2322284Certificate of AnalysisApr 27, 2023 L124970
E2322306Certificate of AnalysisApr 27, 2023 L124970
E2322259Certificate of AnalysisApr 27, 2023 L124970
E2322283Certificate of AnalysisApr 27, 2023 L124970
E2322269Certificate of AnalysisApr 27, 2023 L124970
E2322278Certificate of AnalysisApr 27, 2023 L124970
C2323005Certificate of AnalysisJul 20, 2022 L124970
I2224272Certificate of AnalysisJul 20, 2022 L124970
I2224271Certificate of AnalysisJul 20, 2022 L124970
I2224269Certificate of AnalysisJul 20, 2022 L124970
I2224268Certificate of AnalysisJul 20, 2022 L124970

more

Chemical and Physical Properties

SolubilitySoluble in DMSO (25 mg/ml warm), ethanol (25 mg/ml warm), chloroform, water (< 50 ug/ml) at 25 °C, PBS pH 7.2 (< 50 ug/ml), DMF (~16 mg/ml ), and DMSO:PBS(1:1, pH 7.2) (~0.5 mg/ml ).
SensitivityHeat Sensitive
Melt Point(°C)184 °C

Related Documents

References

1. Cabezas-Cruz A et al..  (2017)  Anaplasma phagocytophilum Infection Subverts Carbohydrate Metabolic Pathways in the Tick Vector, Ixodes scapularis..  Front Cell Infect Microbiol,  (23).  [PMID:28229048]
2. Wu HB et al..  (2017)  Autophagy-induced KDR/VEGFR-2 activation promotes the formation of vasculogenic mimicry by glioma stem cells..  Autophagy,  13  (9): (1528-1542).  [PMID:28812437]
3. Ribeiro FF et al..  (2016)  Axonal elongation and dendritic branching is enhanced by adenosine A2A receptors activation in cerebral cortical neurons..  Brain Struct Funct,  221  (5): (2777-99).  [PMID:26068054]
4. Wu N et al..  (2021)  Berberine ameliorates neuronal AD-like change via activating Pi3k/PGCε pathway..  Biofactors,  47  (4): (587-599).  [PMID:33740285]
5. Jiang T et al..  (2022)  Application of Bone Marrow Mesenchymal Stem Cells Effectively Eliminates Endotoxemia to Protect Rat from Acute Liver Failure Induced by Thioacetamide..  Tissue Eng Regen Med,  19  (2): (403-415).  [PMID:35122584]
6. Lan X et al..  (2017)  Bisphenol A exposure promotes HTR-8/SVneo cell migration and impairs mouse placentation involving upregulation of integrin-ß1 and MMP-9 and stimulation of MAPK and PI3K signaling pathways..  Oncotarget,  (31): (51507-51521).  [PMID:28881663]
7. Song XL et al..  (2017)  Casticin induces apoptosis and G0/G1 cell cycle arrest in gallbladder cancer cells..  Cancer Cell Int,  17  (9).  [PMID:28070171]
8. Xu Z et al..  (2016)  C-C Motif Chemokine Receptor 9 Exacerbates Pressure Overload-Induced Cardiac Hypertrophy and Dysfunction..  J Am Heart Assoc,  (5):   [PMID:27146447]
9. Jiang C et al..  (2019)  CSNK2A1 Promotes Gastric Cancer Invasion Through the PI3K-Akt-mTOR Signaling Pathway..  Cancer Manag Res,  11  (10135-10143).  [PMID:31819646]
10. Hossain ME et al..  (2017)  Direct exposure to mild heat promotes proliferation and neuronal differentiation of neural stem/progenitor cells in vitro..  PLoS One,  12  (12): (e0190356).  [PMID:29287093]
11. Fukushima T et al..  (2019)  Discrimination of Dormant and Active Hematopoietic Stem Cells by G0 Marker Reveals Dormancy Regulation by Cytoplasmic Calcium..  Cell Rep,  29  (12): (4144-4158.e7).  [PMID:31851939]
12. Cao S et al..  (2022)  Effects of cGMP/Akt/GSK-3β signaling pathway on atrial natriuretic peptide secretion in rabbits with rapid atrial pacing..  Front Physiol,  13  (861981).  [PMID:36060704]
13. Dong L et al..  (2019)  FGF10 Enhances Peripheral Nerve Regeneration via the Preactivation of the PI3K/Akt Signaling-Mediated Antioxidant Response..  Front Pharmacol,  10  (1224).  [PMID:31680984]
14. Yan X et al..  (2016)  Ginsenoside Rd. promotes non-amyloidogenic pathway of amyloid precursor protein processing by regulating phosphorylation of estrogen receptor alpha..  Life Sci,      [PMID:27825720]
15. Nagae K et al..  (2018)  Glucagon-like peptide-1 analogue liraglutide facilitates wound healing by activating PI3K/Akt pathway in keratinocytes..  Diabetes Res Clin Pract,  146  (155-161).  [PMID:30367901]
16. Cheng Y et al..  (2014)  High glucose-induced resistance to 5-fluorouracil in pancreatic cancer cells alleviated by 2-deoxy-D-glucose..  Biomed Rep,  (2): (188-192).  [PMID:24649094]
17. Ke H et al..  (2020)  Hydrogen-Rich Saline Regulates Microglial Phagocytosis and Restores Behavioral Deficits Following Hypoxia-Ischemia Injury in Neonatal Mice via the Akt Pathway..  Drug Des Devel Ther,  14  (3827-3839).  [PMID:33061290]
18. Xu Q et al..  (2022)  Interfering with the expression of EEF1D gene enhances the sensitivity of ovarian cancer cells to cisplatin..  BMC Cancer,  22  (628).  [PMID:35672728]
19. Shrestha R et al..  (2014)  Lymphocyte-mediated neuroprotection in in vitro models of excitotoxicity involves astrocytic activation and the inhibition of MAP kinase signalling pathways..  Neuropharmacology,  76 Pt A  (184-93).  [PMID:23831681]
20. Tanaka Y et al..  (2022)  Nectin cell adhesion molecule 4 regulates angiogenesis through Src signaling and serves as a novel therapeutic target in angiosarcoma..  Sci Rep,  12  (4031).  [PMID:35256687]
21. Tanaka Y et al..  (2021)  NECTIN4: A Novel Therapeutic Target for Melanoma..  Int J Mol Sci,  22  (2):   [PMID:33478111]
22. Feng C et al..  (2020)  Neuroprotective Effect of Danhong Injection on Cerebral Ischemia-Reperfusion Injury in Rats by Activation of the PI3K-Akt Pathway..  Front Pharmacol,  11  (298).  [PMID:32218735]
23. Guo W et al..  (2017)  Neurotrophin-4 induces myelin protein zero expression in cultured Schwann cells via the TrkB/PI3K/Akt/mTORC1 pathway..  Anim Cells Syst (Seoul),  21  (2): (84-92).  [PMID:30460055]
24. Slaninova V et al..  (2016)  Notch stimulates growth by direct regulation of genes involved in the control of glycolysis and the tricarboxylic acid cycle..  Open Biol,  (2): (150155).  [PMID:26887408]
25. Liu S et al..  (2022)  Protection of Human Lens Epithelial Cells from Oxidative Stress Damage and Cell Apoptosis by KGF-2 through the Akt/Nrf2/HO-1 Pathway..  Oxid Med Cell Longev,  2022  (6933812).  [PMID:35222803]
26. Pluteanu F & Cribbs LL.  (2011)  Regulation and function of Cav3.1 T-type calcium channels in IGF-I-stimulated pulmonary artery smooth muscle cells..  Am J Physiol Cell Physiol,  300  (3): (C517-25).  [PMID:21148410]
27. Zhang J et al..  (2020)  SNCG promotes the progression and metastasis of high-grade serous ovarian cancer via targeting the PI3K/AKT signaling pathway..  J Exp Clin Cancer Res,  39  (79).  [PMID:32381034]
28. Guan Y & Wang X.  (2021)  Salvianic Acid A Regulates High-Glucose-Treated Endothelial Progenitor Cell Dysfunction via the AKT/Endothelial Nitric Oxide Synthase (eNOS) Pathway..  Med Sci Monit,  27  (e928153).  [PMID:33770068]
29. Wang X et al..  (2018)  Secretory Clusterin Mediates Oxaliplatin Resistance via the Gadd45a/PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma..  J Cancer,  (8): (1403-1413).  [PMID:29721050]
30. Yan W et al..  (2019)  Suppression of SEMA6C promotes preantral follicles atresia with decreased cell junctions in mice ovaries..  J Cell Physiol,  234  (4): (4934-4943).  [PMID:30256425]
31. Sun Y et al..  (2017)  TMEM74 promotes tumor cell survival by inducing autophagy via interactions with ATG16L1 and ATG9A..  Cell Death Dis,  (8): (e3031).  [PMID:29048433]
32. Liu P et al..  (2021)  The NRF2-LOC344887 signaling axis suppresses pulmonary fibrosis..  Redox Biol,  38  (101766).  [PMID:33126057]
33. Chen L et al..  (2021)  The Protective Effects of Shengmai Formula Against Myocardial Injury Induced by Ultrafine Particulate Matter Exposure and Myocardial Ischemia are Mediated by the PI3K/AKT/p38 MAPK/Nrf2 Pathway..  Front Pharmacol,  12  (619311).  [PMID:33762941]
34. Li X et al..  (2019)  The Specific Inhibition of SOD1 Selectively Promotes Apoptosis of Cancer Cells via Regulation of the ROS Signaling Network..  Oxid Med Cell Longev,  2019  (9706792).  [PMID:30911355]
35. Che L et al..  (2019)  Valine increases milk fat synthesis in mammary gland of gilts through stimulating AKT/MTOR/SREBP1 pathway‡..  Biol Reprod,      [PMID:30985894]
36. Zhao M et al..  (2020)  Vinpocetine Protects Against Cerebral Ischemia-Reperfusion Injury by Targeting Astrocytic Connexin43 via the PI3K/AKT Signaling Pathway..  Front Neurosci,  14  (223).  [PMID:32300287]
37. Zhu Y et al..  (2020)  WISP1 indicates poor prognosis and regulates cell proliferation and apoptosis in gastric cancer via targeting AKT/mTOR signaling pathway..  Am J Transl Res,  12  (11): (7297-7311).  [PMID:33312368]
38. Chen S et al..  (2020)  WTAP promotes osteosarcoma tumorigenesis by repressing HMBOX1 expression in an m6A-dependent manner..  Cell Death Dis,  11  (8): (659).  [PMID:32814762]

Solution Calculators